These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27740635)

  • 1. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.
    Kollmann K; Warsch W; Gonzalez-Arias C; Nice FL; Avezov E; Milburn J; Li J; Dimitropoulou D; Biddie S; Wang M; Poynton E; Colzani M; Tijssen MR; Anand S; McDermott U; Huntly B; Green T
    Leukemia; 2017 Apr; 31(4):934-944. PubMed ID: 27740635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
    Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
    Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N
    Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
    Olschok K; Han L; de Toledo MAS; Böhnke J; Graßhoff M; Costa IG; Theocharides A; Maurer A; Schüler HM; Buhl EM; Pannen K; Baumeister J; Kalmer M; Gupta S; Boor P; Gezer D; Brümmendorf TH; Zenke M; Chatain N; Koschmieder S
    Stem Cell Reports; 2021 Nov; 16(11):2768-2783. PubMed ID: 34678208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations.
    Yasuda S; Aoyama S; Yoshimoto R; Li H; Watanabe D; Akiyama H; Yamamoto K; Fujiwara T; Najima Y; Doki N; Sakaida E; Edahiro Y; Imai M; Araki M; Komatsu N; Miura O; Kawamata N
    Int J Hematol; 2021 Oct; 114(4):424-440. PubMed ID: 34165774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
    Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
    Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response.
    Jutzi JS; Marneth AE; Jiménez-Santos MJ; Hem J; Guerra-Moreno A; Rolles B; Bhatt S; Myers SA; Carr SA; Hong Y; Pozdnyakova O; van Galen P; Al-Shahrour F; Nam AS; Mullally A
    Leukemia; 2023 Feb; 37(2):359-369. PubMed ID: 36473980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
    Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C
    Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.
    Tefferi A; Wassie EA; Guglielmelli P; Gangat N; Belachew AA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Pacilli A; Vannucchi AM; Passamonti F
    Am J Hematol; 2014 Aug; 89(8):E121-4. PubMed ID: 24753125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
    Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
    Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the CALR interactome in myeloproliferative neoplasms.
    Pronier E; Cifani P; Merlinsky TR; Berman KB; Somasundara AVH; Rampal RK; LaCava J; Wei KE; Pastore F; Maag JL; Park J; Koche R; Kentsis A; Levine RL
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calreticulin Gene Mutation.
    Wang C; Hu X; Wan Y; Wang S; Qi K; Li Y; Qiao J; Zeng L; Li Z; Fu C; Xu K
    Chemotherapy; 2021; 66(5-6):169-178. PubMed ID: 34666331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
    Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
    Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
    Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
    Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
    Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
    Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
    Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
    Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.